WHO PQ and UNFPA PQ in Ethiopian Reliance and Procurement

1. Key takeaways

WHO PQ and UNFPA PQ carry two-ended value in Ethiopia. At the review end, the fourth edition of EFDA-GDL-046 lists both alongside 8 stringent regulatory authorities (SRAs) as acceptable market-access evidence under the reliance pathway; at the procurement end, the two prequalifications are the routine entry credentials for United Nations agencies and international buyers. For a single prequalification certificate, one investment becomes effective in two separate arenas at once, which makes it the highest-return compliance asset in this market. For manufacturers without an SRA approval of their own, this dual function is even more consequential: the same document both shortens the regulatory route and opens procurement doors that would otherwise stay closed until local registration is complete.

2. Legal basis

3. Expert insights

Insight 1: PQ sits alongside the SRAs, which gives a non-state body quasi-regulatory standing.

The reliance evidence listed in Section 9.4 of EFDA-GDL-046 comprises 8 national regulatory authorities (US FDA, Japan’s MHLW, Australia’s TGA, Singapore’s HSA, the competent authorities of the 27 EU member states, the UK’s MHRA, Health Canada, and Korea’s MFDS), plus WHO PQ and UNFPA PQ. For manufacturers without an approval from any of the SRAs, PQ is the only reliance entry point that does not require a national regulatory approval. That positioning is unusual: a UN program assessment acquires the same formal standing as a national regulator’s decision, and applicants can build their reliance argument on it.

Insight 2: At the review end, PQ works as evidence substitution, not automatic approval.

The reliance pathway reduces duplicated review workload; it does not abolish EFDA’s power of examination. Together with the proportionality principle of Article 19(1) and the GMP, dossier and laboratory testing requirements of Article 20(4), EFDA can still impose local conditions such as labeling, UMDN classification and a local agent. Treating PQ as a get-out-of-review certificate loses points precisely at the localization stage, where most reliance applications are actually decided.

Insight 3: The evaluation yardsticks at the procurement end and the review end differ.

The review end looks at sufficiency of evidence; the procurement end looks at sustainability of supply and price. The same PQ certificate is used in the two arenas for different reasons, so the supporting materials must differ as well: the review end needs the PQ certificate together with a summary of the corresponding technical documentation, while the procurement end needs manufacturing capacity, delivery records and after-sales network evidence. Preparing one package for both audiences serves neither well.

Insight 4: The lists are dynamic.

EFDA-GDL-046 states that the SRA list will be updated as needed; the WHO PQ and UNFPA PQ lists are themselves published product by product. All three must be verified against the currently published versions, and a historical list cannot support a submission argument. A certificate valid last quarter may sit on a revised list today, and the burden of confirming currency rests with the applicant at the moment of filing.

Insight 5: IVD manufacturers benefit most visibly.

WHO operates a dedicated prequalification procedure for IVDs, and IVDs in Ethiopia are classified under Class A–D, with Class C and above additionally required to submit safety and performance evidence within one year of market placement. IVD products already holding WHO PQ can reuse their existing materials directly in both the reliance pathway and the evidence-submission step, compressing two documentation efforts into one and materially shortening the route to both approval and tender eligibility.

4. Practical recommendations

1. Judge reliance-pathway feasibility first: confirm whether the product already holds an approval from one of the 8 SRAs, or WHO PQ / UNFPA PQ.
2. Sequence PQ priorities: for products targeting public and institutional procurement, advance WHO PQ first; for reproductive-health products, evaluate UNFPA PQ first.
3. Reuse PQ materials in both directions: assemble the PQ certificate and technical summary for the review end, and capacity and delivery records for the procurement end.
4. Do not skip localization requirements: even on the reliance pathway, English labeling and instructions for use, UMDN coding, the local agent agreement and the CoC remain necessary.
5. Re-check the lists before every submission: the SRA list, the WHO PQ list and the UNFPA PQ list must each be verified against the currently published version.
6. Plan the vigilance system in parallel: reliance does not exempt post-market obligations; the vigilance and PMS systems must be stood up alongside the submission.

5. Verification checklist

• □ Confirmed whether the product holds an SRA approval or PQ evidence
• □ The current list of Section 9.4 of EFDA-GDL-046 has been checked
• □ The current published WHO PQ / UNFPA PQ lists have been checked
• □ The technical documentation summary required for the reliance pathway has been prepared
• □ English labeling, instructions for use and UMDN coding have been prepared in parallel
• □ The local agent agreement and CoC are in place
• □ The vigilance and post-market surveillance systems have been established

Regulatory information verified as of October 29, 2026. The reliance pathway and PQ evidence requirements listed in this article are governed by Section 9.4 of the fourth edition of EFDA-GDL-046 and the currently published WHO and UNFPA lists; when the lists are adjusted, they must be re-checked.

Local resource in Ethiopia: GRZAN supports manufacturers from the Chinese mainland and overseas in engaging with the Ethiopian Food and Drug Authority (EFDA) on market authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent structuring and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and post-market surveillance systems. Service capabilities cover product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), market authorization applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles conformity reasoning, label and instruction-for-use localization in English, and vigilance reporting with field safety corrective action support. Contact: hito.lin@grzan.cn; website www.grzan.cn. For reliance-pathway arguments, PQ strategy and local authorized representative support in the Ethiopian market, GRZAN can also be reached at info@grzanglobal.com.